EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Nature Medicine

• Publication date

  2011-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/nm.2341PMID 21516087PMCID PMC3938446
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hepatitis C virus entry.

  2013cited by this paper
• A chemical and phosphoproteomic characterization of dasatinib action in lung cancer

  2010cited by this paper
• Claudin Association with CD81 Defines Hepatitis C Virus Entry

  2010cited by this paper
• Practical evaluation of a mouse with chimeric human liver model for hepatitis C virus infection using an NS3-4A protease inhibitor.

  2010cited by this paper
• Kinase inhibitors in the treatment of chronic hepatitis C virus

  2010cited by this paper
• Virus-host interactions in hepatitis C virus infection: implications for molecular pathogenesis and antiviral strategies.

  2010cited by this paper
• Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation

  2010cited by this paper
• Glucocorticosteroids increase cell entry by hepatitis C virus.

  2010cited by this paper
• Inhibition of hepatitis C virus infection by anti‐claudin‐1 antibodies is mediated by neutralization of E2–CD81–Claudin‐1 associations

  2010cited by this paper
• Therapeutic Silencing of MicroRNA-122 in Primates with Chronic Hepatitis C Virus Infection

  2010cited by this paper
• Architecture of Eph receptor clusters

  2010cited by this paper
• Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes.

  2010cited by this paper
• Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

  2010cited by this paper
• Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.

  2009cited by this paper
• siRNA and shRNA screens advance key understanding of host factors required for HIV-1 replication

  2009cited by this paper
• Overexpression of EphA2, MMP‐9, and MVD‐CD34 in hepatocellular carcinoma: Implications for tumor progression and prognosis

  2009cited by this paper
• Human occludin is a hepatitis C virus entry factor required for infection of mouse cells

  2009cited by this paper
• Dasatinib dosing strategies in Philadelphia chromosome-positive leukemia

  2009cited by this paper
• A genome-wide genetic screen for host factors required for hepatitis C virus propagation

  2009cited by this paper
• Simultaneous Quantification of Erlotinib, Gefitinib, and Imatinib in Human Plasma by Liquid Chromatography Tandem Mass Spectrometry

  2009cited by this paper
• EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt.

  2009cited by this paper
• Integrin signalling at a glance

  2009cited by this paper
• Efficient and stable transduction of resting B lymphocytes and primary chronic lymphocyte leukemia cells using measles virus gp displaying lentiviral vectors.

  2009cited by this paper
• Receptor Complementation and Mutagenesis Reveal SR-BI as an Essential HCV Entry Factor and Functionally Imply Its Intra- and Extra-Cellular Domains

  2009cited by this paper
• University of Birmingham Polarization restricts hepatitis C virus entry into HepG2 hepatoma cells.

  2009cited by this paper
• CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells

  2009cited by this paper
• EphA2 engages Git1 to suppress Arf6 activity modulating epithelial cell-cell contacts.

  2009cited by this paper
• Treatment failure in hepatitis C: mechanisms of non-response.

  2009cited by this paper
• Absence of viral interference and different susceptibility to interferon between hepatitis B virus and hepatitis C virus in human hepatocyte chimeric mice.

  2009cited by this paper
• The epidermal growth factor receptor ligands at a glance

  2009cited by this paper
• Control of tight junctional sealing: roles of epidermal growth factor and prostaglandin E2.

  2009cited by this paper
• Nonstructural 3/4A protease of hepatitis C virus activates epithelial growth factor–induced signal transduction by cleavage of the T‐cell protein tyrosine phosphatase

  2009cited by this paper
• Polarization Restricts Hepatitis C Virus Entry into HepG2 Hepatoma Cells

  2009cited by this paper
• Mouse-Specific Residues of Claudin-1 Limit Hepatitis C Virus Genotype 2a Infection in a Human Hepatocyte Cell Line

  2009cited by this paper
• Metabolism and Disposition of Dasatinib after Oral Administration to Humans

  2008cited by this paper
• Eph, a Protein Family Coming of Age: More Confusion, Insight, or Complexity?

  2008cited by this paper
• Hepatitis C Virus Entry*

  2008cited by this paper
• RNA interference screen for human genes associated with West Nile virus infection

  2008cited by this paper
• STRING 8—a global view on proteins and their functional interactions in 630 organisms

  2008cited by this paper
• Modeling oncogene addiction using RNA interference

  2008cited by this paper
• Identification of Host Proteins Required for HIV Infection Through a Functional Genomic Screen

  2008cited by this paper
• Host neutralizing responses and pathogenesis of hepatitis C virus infection

  2008cited by this paper
• Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion.

  2008cited by this paper
• Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma.

  2008cited by this paper
• Bromodomain Protein Brd4 Regulates Human Immunodeficiency Virus Transcription through Phosphorylation of CDK9 at Threonine 29

  2008cited by this paper
• Scavenger Receptor Class B Is Required for Hepatitis C Virus Uptake and Cross-Presentation by Human Dendritic Cells

  2008cited by this paper
• The Hepatitis C Virus Non‐Structural Protein NS5A Alters the Trafficking Profile of the Epidermal Growth Factor Receptor

  2008cited by this paper
• fdrtool: a versatile R package for estimating local and tail area-based false discovery rates

  2008cited by this paper
• University of Birmingham CD81 and claudin 1 coreceptor association: Role in hepatitis C virus entry

  2008cited by this paper
• Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C

  2007cited by this paper
• Cell integrins: commonly used receptors for diverse viral pathogens.

  2007cited by this paper
• Characterization of Fusion Determinants Points to the Involvement of Three Discrete Regions of Both E1 and E2 Glycoproteins in the Membrane Fusion Process of Hepatitis C Virus

  2007cited by this paper
• Effect of Cell Polarization on Hepatitis C Virus Entry

  2007cited by this paper
• Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia.

  2007cited by this paper
• Isolation and Characterization of Broadly Neutralizing Human Monoclonal Antibodies to the E1 Glycoprotein of Hepatitis C Virus

  2007cited by this paper
• Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry

  2007cited by this paper
• Hepatitis C virus cell‐cell transmission in hepatoma cells in the presence of neutralizing antibodies

  2007cited by this paper
• Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81

  2007cited by this paper
• Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras.

  2006cited by this paper
• Hepatitis C virus core protein promotes proliferation of human hepatoma cells through enhancement of transforming growth factor alpha expression via activation of nuclear factor-kappaB.

  2006cited by this paper
• Evaluation of the Absolute Oral Bioavailability and Bioequivalence of Erlotinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in a Randomized, Crossover Study in Healthy Subjects

  2006cited by this paper
• Characterization of the Early Steps of Hepatitis C Virus Infection by Using Luciferase Reporter Viruses

  2006cited by this paper
• MAPK interacts with occludin and mediates EGF-induced prevention of tight junction disruption by hydrogen peroxide.

  2006cited by this paper
• High Density Lipoprotein Inhibits Hepatitis C Virus-neutralizing Antibodies by Stimulating Cell Entry via Activation of the Scavenger Receptor BI*

  2006cited by this paper
• Hepatitis C virus core protein promotes proliferation of human hepatoma cells through enhancement of transforming growth factor α expression via activation of nuclear factor-κB

  2006cited by this paper
• Initiation of Hepatitis C Virus Infection Is Dependent on Cholesterol and Cooperativity between CD81 and Scavenger Receptor B Type I

  2006cited by this paper
• Viral and Cellular Determinants of the Hepatitis C Virus Envelope-Heparan SulfateInteraction

  2006cited by this paper
• Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma.

  2006cited by this paper
• Hepatitis C Virus Entry Depends on Clathrin-Mediated Endocytosis

  2006cited by this paper
• Morphological and biochemical characterization of a human liver in a uPA‐SCID mouse chimera

  2005cited by this paper
• Complete Replication of Hepatitis C Virus in Cell Culture

  2005cited by this paper
• EphA2 Phosphorylates the Cytoplasmic Tail of Claudin-4 and Mediates Paracellular Permeability*

  2005cited by this paper
• Characterization of host‐range and cell entry properties of the major genotypes and subtypes of hepatitis C virus

  2005cited by this paper
• Gene expression profiles of HeLa Cells impacted by hepatitis C virus non-structural protein NS4B.

  2005cited by this paper
• Robust hepatitis C virus infection in vitro.

  2005cited by this paper
• Erlotinib in previously treated non-small-cell lung cancer.

  2005cited by this paper
• Regulation of Microfilament Organization by Kaposi Sarcoma-associated Herpes Virus-cyclin·CDK6 Phosphorylation of Caldesmon*

  2005cited by this paper
• Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models

  2004cited by this paper
• Epidermal Growth Factor Receptor Activation Differentially Regulates Claudin Expression and Enhances Transepithelial Resistance in Madin-Darby Canine Kidney Cells*

  2004cited by this paper
• More than meets the eye

  2004cited by this paper
• Pharmacokinetics and pharmacodynamics: maximizing the clinical potential of Erlotinib (Tarceva).

  2003cited by this paper
• Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon.

  2003cited by this paper
• Infectious Hepatitis C Virus Pseudo-particles Containing Functional E1–E2 Envelope Protein Complexes

  2003cited by this paper
• Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates.

  2002cited by this paper
• Ligand-induced, receptor-mediated dimerization and activation of EGF receptor.

  2002cited by this paper
• c-Cbl-dependent EphA2 protein degradation is induced by ligand binding.

  2002cited by this paper
• The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus

  2002cited by this paper
• Transactivation of the Epidermal Growth Factor Receptor in Colonic Epithelial Cells by Carbachol Requires Extracellular Release of Transforming Growth Factor-α*

  2002cited by this paper
• The Protein Kinase Complement of the Human Genome

  2002cited by this paper
• Negative regulation of EphA2 receptor by Cbl.

  2002cited by this paper
• Expression of transforming growth factor-alpha mRNA in livers of patients with chronic viral hepatitis and hepatocellular carcinoma.

  2000cited by this paper
• Phosphorylation of Tyrosine Residues in the Kinase Domain and Juxtamembrane Region Regulates the Biological and Catalytic Activities of Eph Receptors

  2000cited by this paper
• De novo expression of pp125FAK in human macrophages regulates CSK distribution and MAP kinase activation but does not affect focal contact structure

  1999cited by this paper
• A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays

  1999cited by this paper
• Replication of Subgenomic Hepatitis C Virus Rnas in a Hepatoma Cell Line

  1999cited by this paper
• Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line.

  1999cited by this paper
• Response to transforming growth factor α (TGFα) and epidermal growth factor (EGF) in hepatocytes: Lower EGF receptor affinity of TGFα is associated with more sustained activation of p42/p44 mitogen‐activated protein kinase and greater efficacy in stimulation of DNA synthesis

  1998cited by this paper
• Response to transforming growth factor alpha (TGFalpha) and epidermal growth factor (EGF) in hepatocytes: lower EGF receptor affinity of TGFalpha is associated with more sustained activation of p42/p44 mitogen-activated protein kinase and greater efficacy in stimulation of DNA synthesis.

  1998cited by this paper
• Binding of hepatitis C virus to CD81.

  1998cited by this paper
• Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection.

  1997cited by this paper

• Zika virus entry inhibitors.

  2026cites this paper
• Protein tyrosine phosphatase delta is a STAT3-phosphatase and suppressor of metabolic liver disease

  2025cites this paper
• Longitudinal analysis of hsa-miR-3163, hsa-miR-124-3p, hsa-miR-548c-3p, and hsa-miR-27a-3p as prognostic biomarkers in HIV-infected patients

  2025cites this paper
• Dcaf15-mediated EphA2 degradation triggers disruption of the blood-brain barrier during Streptococcus suis meningitis

  2025cites this paper
• Exploiting Host Kinases to Combat Dengue Virus Infection and Disease.

  2025cites this paper
• Molecular Roadmap of COVID‐19: From Viral Entry to Therapeutic Targets

  2025cites this paper
• Neurobiology of COVID‐19‐Associated Psychosis/Schizophrenia: Implication of Epidermal Growth Factor Receptor Signaling

  2025cites this paper
• Intergraded multi omics analysis identifies antiviral host factor and pathway controlling HIV infection

  2025cites this paper
• Validation of signature molecular profiles of advanced HCV liver disease in hepatocellular carcinoma patients

  2025cites this paper
• Review of the relationship between growth hormone and SARS-CoV-2 infection

  2025cites this paper
• LMP2A regulates S901 phosphorylation of EphA2 to maintain EBV latent infection in gastric cancer

  2025cites this paper
• Transcriptomic analysis of DENV-2-infected human dermal fibroblasts identified potential mechanisms that suppressed ZIKV replication during sequential coinfection

  2025cites this paper
• Challenges of broad-spectrum antiviral drug discovery and development for emerging pathogens.

  2025cites this paper
• Protein tyrosine kinase Src suppresses hepatitis C virus particle release through regulation of Ndrg1

  2025cites this paper
• The role of tetraspanins in organ fibrosis: mechanisms and therapeutic perspectives

  2025cites this paper
• Prevention of liver cancer in the era of next-generation antivirals and obesity epidemic.

  2025cites this paper
• Natural Pangenotypic Hepatitis C Virus Preventives‐ a Hope With Terfenadine

  2025cites this paper
• Pathogenesis, prevention, and therapeutic advances in hepatitis B, C, and D

  2025cites this paper
• Synthesis of a 3,7-Disubstituted Isothiazolo[4,3-b]pyridine as a Potential Inhibitor of Cyclin G-Associated Kinase

  2024cites this paper
• The interference between SARS-COV-2 and Alzheimer's disease:Potential immunological and neurobiological crosstalk from a kinase perspective reveals a delayed pandemic.

  2024cites this paper
• Targeting NTCP for liver disease treatment: A promising strategy

  2024cites this paper
• EGFR core fucosylation, induced by hepatitis C virus, promotes TRIM40-mediated-RIG-I ubiquitination and suppresses interferon-I antiviral defenses

  2024cites this paper
• Interferon-induced transmembrane protein-1 competitively blocks Ephrin receptor A2-mediated Epstein–Barr virus entry into epithelial cells

  2024cites this paper
• Mechanisms and therapeutic targets of ErbB family receptors in hepatocellular carcinoma: a narrative review

  2024cites this paper
• Pan-cancer molecular signatures connecting aspartate transaminase (AST) to cancer prognosis, metabolic and immune signatures

  2024cites this paper
• Carcinome hépatocellulaire et virus de l’hépatite C, stratégies diagnostiques et thérapeutiques

  2024cites this paper
• Harnessing host enhancers of SARS-CoV-2 entry as novel targets for antiviral therapy.

  2024cites this paper
• Epidermal Growth Factor Receptor Inhibition With Erlotinib in Liver: Dose De-Escalation Pilot Trial as an Initial Step in a Chemoprevention Strategy

  2024cites this paper
• Back-pocket optimization of 2-aminopyrimidine-based macrocycles leads to potent dual EPHA2/GAK kinase inhibitors with antiviral activity

  2024cites this paper
• Viruses exploit growth factor mechanisms to achieve augmented pathogenicity and promote tumorigenesis

  2024cites this paper
• Integrating pharmacokinetics and network pharmacology to decipher the efficacy of Fufang Qinlan oral liquid on post infectious cough

  2024cites this paper
• Dissecting the Epstein–Barr virus entry pathway into astrocytes: unfolding the involvement of endosomal trafficking

  2024cites this paper
• Exploring 4,7-Disubstituted Pyrimido[4,5-d]pyrimidines as Antiviral and Anticancer Agents

  2024cites this paper
• A Comprehensive Quality Evaluation for Gentiana Rigescens Franch. by Fingerprinting Combined with Chemometrics and Network Pharmacology

  2024cites this paper
• SARS-CoV-2 aberrantly elevates mitochondrial bioenergetics to induce robust virus propagation

  2024cites this paper
• Reduction of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant infection by blocking the epidermal growth factor receptor (EGFR) pathway

  2024cites this paper
• After the Storm: Persistent Molecular Alterations Following HCV Cure

  2024cites this paper
• Host-Targeting Antivirals for Chronic Viral Infections of the Liver.

  2024cites this paper
• A review: cellular attachment and entry factors of human tumor-associated viruses

  2024cites this paper
• Hepatitis E Virus: What More Do We Need to Know?

  2024cites this paper
• FGFR1-mediated enhancement of foot-and-mouth disease virus entry.

  2024cites this paper
• A comprehensive overview on the crosstalk between microRNAs and viral pathogenesis and infection

  2024cites this paper
• Immortalized hepatocyte-like cells: A competent hepatocyte model for studying clinical HCV isolate infection

  2024cites this paper
• Functional Role of Hepatitis C Virus NS5A in the Regulation of Autophagy

  2024cites this paper
• JNK Signaling Pathways and Oncoviruses

  2024cites this paper
• Hepatitis B virus entry, assembly, and egress

  2024cites this paper
• Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication

  2024cites this paper
• Tim-1 and Tim-4 mediate entry of the human Kaposi’s sarcoma-associated herpesvirus and the related rhesus monkey rhadinovirus

  2024cites this paper
• CAM-A-dependent HBV core aggregation induces apoptosis through ANXA1

  2024cites this paper
• Identification critical host factors for Japanese encephalitis virus replication via CRISPR screening of human sgRNA library.

  2024cites this paper
• Antagonism of epidermal growth factor receptor signaling favors hepatitis E virus life cycle

  2024cites this paper
• Back-Pocket Optimization of 2-Aminopyrimidine-Based Macrocycles Leads to Potent EPHA2/GAK Kinase Inhibitors.

  2024cites this paper
• Both Maternal and Newborn IgMs Inhibit Transmissible Gastroenteritis Virus Internalization in LLC-PK1 Cells

  2023cites this paper
• Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2

  2023cites this paper
• Multiscale network analysis identifies potential receptors for SARS‐CoV‐2 and reveals their tissue‐specific and age‐dependent expression

  2023cites this paper
• Gene Expression Profiling Unravels Hepatitis C Virus (HCV) Infection-induced Temporal Alteration of Gene Expression in Hepatocellular Carcinoma (HCC)

  2023cites this paper
• Targeting epidermal growth factor receptor signalling pathway: A promising therapeutic option for COVID‐19

  2023cites this paper
• A Genome-Wide RNAi Screen Reveals Common Host–Virus Gene Signatures: Implication for Dengue Antiviral Drug Discovery

  2023cites this paper
• Unraveling the Significance of EPH/Ephrin Signaling in Liver Cancer: Insights into Tumor Progression and Therapeutic Implications

  2023cites this paper
• Role of Virus-Induced EGFR Trafficking in Proviral Functions

  2023cites this paper
• Single-cell analysis reveals lasting immunological consequences of influenza infection and respiratory immunization in the pig lung

  2023cites this paper
• Hepatitis C Virus-Lipid Interplay: Pathogenesis and Clinical Impact

  2023cites this paper
• Interferon alpha inducible protein 6 is a negative regulator of innate immune responses by modulating RIG-I activation

  2023influential citation
• Host factor TNK2 is required for influenza virus infection

  2023cites this paper
• Role of sodium taurocholate cotransporting polypeptide (NTCP) in HBV-induced hepatitis: Opportunities for developing novel therapeutics.

  2023cites this paper
• Roles of epidermal growth factor receptor, claudin-1 and occludin in multi-step entry of hepatitis C virus into polarized hepatoma spheroids

  2023cites this paper
• EGF receptor modulates HEV entry in human hepatocytes

  2023influential citation
• EPHA2 Receptor as a Possible Therapeutic Target in Viral Infections.

  2023cites this paper
• Unmet Needs in the Post-Direct-Acting Antiviral Era: Hepatocarcinogenesis After Hepatitis C Virus Eradication.

  2023cites this paper
• Antiviral mechanisms of sorafenib against foot-and-mouth disease virus via c-RAF and AKT/PI3K pathways

  2023cites this paper
• A Synopsis of Hepatitis C Virus Treatments and Future Perspectives

  2023cites this paper
• Axon guidance molecules in liver pathology: Journeys on a damaged passport

  2023cites this paper
• Identification of a receptor tyrosine kinase inhibitor CP-724714 inhibits SADS-CoV related swine diarrhea coronaviruses infection in vitro

  2023cites this paper
• Discovery of PLpro and Mpro Inhibitors for SARS-CoV-2

  2023cites this paper
• Association between Statins Types with Incidence of Liver Cancer: An Updated Meta-analysis

  2023cites this paper
• Recent Updates on Viral Oncogenesis: Available Preventive and Therapeutic Entities

  2023cites this paper
• TRIM26 restricts Epstein–Barr virus infection in nasopharyngeal epithelial cells through K48‐linked ubiquitination of HSP‐90β

  2023cites this paper
• Preparing for the next viral threat with broad-spectrum antivirals

  2023cites this paper
• Genetic and pharmacological perturbation of hepatitis-C virus entry.

  2023cites this paper
• GB Virus B and Hepatitis C Virus, Distantly Related Hepaciviruses, Share an Entry Factor, Claudin-1

  2023cites this paper
• The matrix metalloproteinase ADAM10 supports hepatitis C virus entry and cell-to-cell spread via its sheddase activity

  2023cites this paper
• Molecular characterization and immune response of suppressor of cytokine signaling 5b from redlip mullet (Planiliza haematocheilus): Disclosing its anti-viral potential and effect on cell proliferation.

  2023cites this paper
• Cell-based cccDNA reporter assay combined with functional genomics identifies YBX1 as HBV cccDNA host factor and antiviral candidate target

  2022cites this paper
• Lipofectamine 2000™ at transfection dose promotes EphA2 transcription in an HDAC4-dependent manner to reduce its cytotoxicity

  2022cites this paper
• β-arrestins and G protein-coupled receptor kinases in viral entry: A graphical review.

  2022cites this paper
• FDA-Approved Inhibitors of RTK/Raf Signaling Potently Impair Multiple Steps of In Vitro and Ex Vivo Influenza A Virus Infections

  2022cites this paper
• Targeting Host Tyrosine Kinase Receptor EPHA2 Signaling Affects Uropathogen Infection in Human Bladder Epithelial Cells

  2022cites this paper
• Distantly related hepaciviruses share common entry factor, Claudin-1

  2022cites this paper
• Porcine Epidemic Diarrhea Virus: An Updated Overview of Virus Epidemiology, Virulence Variation Patterns and Virus–Host Interactions

  2022cites this paper
• An RNAi screen reveals common host-virus gene signatures: implication for anti-viral drug discovery

  2022cites this paper
• The roles of epidermal growth factor receptor in viral infections

  2022influential citation
• Serotype I and II Feline Coronavirus Replication and Gene Expression Patterns of Feline Cells—Building a Better Understanding of Serotype I FIPV Biology

  2022cites this paper
• Pseudotyped lentiviral vectors: Ready for translation into targeted cancer gene therapy?

  2022cites this paper
• EGFR Activation Impairs Antiviral Activity of Interferon Signaling in Brain Microvascular Endothelial Cells During Japanese Encephalitis Virus Infection

  2022cites this paper
• Entry Inhibitors of Hepatitis C Virus.

  2022cites this paper
• A single mutation in the E2 glycoprotein of hepatitis C virus broadens the claudin specificity for its infection

  2022cites this paper
• Signaling Induced by Chronic Viral Hepatitis: Dependence and Consequences

  2022cites this paper
• Scavenger Receptors in the Pathogenesis of Viral Infections

  2022cites this paper
• HIV-1-Mediated Acceleration of Oncovirus-Related Non-AIDS-Defining Cancers

  2022cites this paper
• Transcriptome analysis method based on differential distribution evaluation

  2022cites this paper